Clinical effectiveness of nirmatrelvir plus ritonavir for patients with COVID-19 and preexisting psychiatric disorders

References

• Lai CC, Wang CY, Wang YH, et al. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020;55(4):105946. doi: 10.1016/j.ijantimicag.2020.105946
   PubMed Web of Science ®Google Scholar
• World Health Organization. [cited 2023 Jan 27]. Available from: https://covid19.who.int/
   Google Scholar
• Ceban F, Nogo D, Carvalho IP, et al. Association between mood disorders and risk of COVID-19 infection, hospitalization, and death: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(10):1079–1091. doi: 10.1001/jamapsychiatry.2021.1818
   PubMed Web of Science ®Google Scholar
• Khoury E, Nevitt S, Madsen WR, et al. Differences in outcomes and factors associated with mortality among patients with SARS-CoV-2 infection and cancer compared with those without cancer: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(5):e2210880. doi: 10.1001/jamanetworkopen.2022.10880
   PubMed Web of Science ®Google Scholar
• Vai B, Mazza MG, Delli Colli C, et al. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. Lancet Psychiatry. 2021;8(9):797–812. doi: 10.1016/S2215-0366(21)00232-7
   PubMed Web of Science ®Google Scholar
• Bepouka B, Mayasi N, Mandina M, et al. Risk factors for mortality in COVID-19 patients in sub-saharan Africa: a systematic review and meta-analysis. PLoS One. 2022;17(10):e0276008. doi: 10.1371/journal.pone.0276008
   PubMed Web of Science ®Google Scholar
• Dorjee K, Kim H, Bonomo E, et al. Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: a comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients. PLoS One. 2020;15(12):e0243191. doi: 10.1371/journal.pone.0243191
   PubMed Web of Science ®Google Scholar
• Fathi M, Vakili K, Sayehmiri F, et al. The prognostic value of comorbidity for the severity of COVID-19: a systematic review and meta-analysis study. PLOS ONE. 2021;16(2):e0246190. doi: 10.1371/journal.pone.0246190
   PubMed Web of Science ®Google Scholar
• Shi C, Wang L, Ye J, et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):663. doi: 10.1186/s12879-021-06369-0
   PubMed Web of Science ®Google Scholar
• Shi Q, Wang Z, Liu J, et al. Risk factors for poor prognosis in children and adolescents with COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2021;41:101155. doi: 10.1016/j.eclinm.2021.101155
   PubMedGoogle Scholar
• Tazerji SS, Shahabinejad F, Tokasi M, et al. Global data analysis and risk factors associated with morbidity and mortality of COVID-19. Gene Rep. 2022;26:101505. doi: 10.1016/j.genrep.2022.101505
   PubMed Web of Science ®Google Scholar
• Wingert A, Pillay J, Gates M, et al. Risk factors for severity of COVID-19: a rapid review to inform vaccine prioritisation in Canada. BMJ Open. 2021;11(5):e044684. doi: 10.1136/bmjopen-2020-044684
   PubMed Web of Science ®Google Scholar
• Nemani K, Li C, Olfson M, et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry. 2021;78(4):380–386. doi: 10.1001/jamapsychiatry.2020.4442
   PubMed Web of Science ®Google Scholar
• Toubasi AA, AbuAnzeh RB, Tawileh HBA, et al. A meta-analysis: the mortality and severity of COVID-19 among patients with mental disorders. Psych Res. 2021;299:113856. doi: 10.1016/j.psychres.2021.113856
   PubMed Web of Science ®Google Scholar
• Fond G, Pauly V, Leone M, et al. Disparities in intensive care unit admission and mortality among patients with schizophrenia and COVID-19: a national cohort study. Schizophr Bull. 2021;47(3):624–634. doi: 10.1093/schbul/sbaa158
   PubMed Web of Science ®Google Scholar
• Wang Q, Xu R, Volkow ND. Increased risk of COVID‐19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2021;20(1):124–130. doi: 10.1002/wps.20806
   PubMed Web of Science ®Google Scholar
• De Picker LJ, Yolken R, Benedetti F, et al. Viewpoint vertical bar European COVID-19 exit strategy for people with severe mental disorders: too little, but not yet too late. Brain Behav Immun. 2021;94:15–17. doi: 10.1016/j.bbi.2021.01.008
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. [cited 2024 Dec 26]. Available from: https://www.covid19treatmentguidelines.nih.gov/tables/management-of-nonhospitalized-adults-summary/
   Google Scholar
• CDC. [cited 2023 Jan 29]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/clinical-considerations-index.html
   Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022;386(15):1397–1408. doi: 10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Ganatra S, Dani SS, Ahmad J, et al. Oral nirmatrelvir and ritonavir in non-hospitalized vaccinated patients with covid-19. Clinical Infectious Diseases. 2022;76(4):563–572. doi: 10.1093/cid/ciac673
   Web of Science ®Google Scholar
• Turk MA, Landes SD, Formica MK, et al. Intellectual and developmental disability and COVID-19 case-fatality trends: TriNetX analysis. Disabil Health J. 2020;13(3):100942. doi: 10.1016/j.dhjo.2020.100942
   PubMed Web of Science ®Google Scholar
• Taquet M, Luciano S, Geddes JR, et al. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130–140. doi: 10.1016/S2215-0366(20)30462-4
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Q, Davis PB, et al. Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. World Psychiatry. 2022;21(1):124–132. doi: 10.1002/wps.20921
   PubMed Web of Science ®Google Scholar
• Wang W, Wang CY, Wang SI, et al. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101619. doi: 10.1016/j.eclinm.2022.101619
   PubMedGoogle Scholar
• Tsai Y-W, Tsai C-F, Wu J-Y, et al. The risk of methicillin-resistant Staphylococcus aureus infection following COVID-19 and influenza: a retrospective cohort study from the TriNetX network. J Infect. 2023;86(3):256–308. doi: 10.1016/j.jinf.2023.01.006
   Web of Science ®Google Scholar
• Liu T-H, Wu J-Y, Huang P-Y, et al. The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: a retrospective cohort study including 91,528 patients. J Infect. 2023;86(3):256. doi: 10.1016/j.jinf.2023.01.014
   Web of Science ®Google Scholar
• Hsu W-H, Tsai Y-W, Wu J-Y, et al. Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors. J Infect. 2023;86(4):e107–e110. doi: 10.1016/j.jinf.2023.02.007
   PubMed Web of Science ®Google Scholar
• Chang Y-H, Liu T-H, Wu J-Y, et al. The association between corticosteroids and aspergillosis among COVID-19 patients. J Infect. 2023;86(4):394–396. doi: 10.1016/j.jinf.2023.01.034
   PubMed Web of Science ®Google Scholar
• Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416–427. doi: 10.1016/S2215-0366(21)00084-5
   PubMed Web of Science ®Google Scholar
• De Picker LJ, Leboyer M, Geddes JR, et al. Association between serum lithium level and incidence of COVID-19 infection. Br J Psychiatry. 2022;221(1):425–427. doi: 10.1192/bjp.2022.42
   PubMed Web of Science ®Google Scholar
• Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19 a randomized clinical trial. J Am Med Assoc. 2020;324(22):2292–2300. doi: 10.1001/jama.2020.22760
   PubMed Web of Science ®Google Scholar
• Heinze G, Jüni P. An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J. 2011;32(14):1704–1708. doi: 10.1093/eurheartj/ehr031
   PubMed Web of Science ®Google Scholar
• Ganatra S, Dani SS, Ahmad J, et al. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019. Clin Infect Dis. 2023;76(4):563–572.
   PubMed Web of Science ®Google Scholar
• Wong CK, Au IC, Lau KT, et al. Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA. 2 wave: a retrospective cohort study. Lancet Infect Dis. 2022;22(12):1681–1693. doi: 10.1016/S1473-3099(22)00507-2
   PubMed Web of Science ®Google Scholar
• Control CfD, prevention: underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. Atlanta (GA): Centers for Disease Control and Prevention (CDC); 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html
   Google Scholar
• Marzolini C, Kuritzkes DR, Marra F, et al. Recommendations for the management of drug–drug interactions between the COVID‐19 antiviral nirmatrelvir/ritonavir (paxlovid) and comedications. Clin Pharm Therapeutics. 2022;112(6):1191–1200. doi: 10.1002/cpt.2646
   PubMed Web of Science ®Google Scholar
• Liu C-I, Goh KK, Chen C-H. Neutropenia after the coadministration of clozapine and nirmatrelvir-ritonavir in a patient with SARS-CoV-2 infection: a case report with a literature review. Front Psychiatry. 2022;13:1096006. doi: 10.3389/fpsyt.2022.1096006
   PubMed Web of Science ®Google Scholar